GlassScriptPhysician profile
Angela V Dussan
NPI 1205115474
$5,646.97
in general payments reported to CMS, 2019-2025
23 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 89% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $224 · 2021: $517 · 2022: $1,006 · 2023: $795 · 2024: $919 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $592.33 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Sight Sciences, INC. | $582.48 | 2021-2024 | Tearcare System, Omni Surgical System |
| Coopervision INC. | $575.90 | 2020-2025 | Ortho-K Contact Lens, Myday Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $563.96 | 2022-2025 | Miebo, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $493.19 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $480.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $435.76 | 2021 | |
| Sun Pharmaceutical Industries INC. | $352.99 | 2019-2025 | Cequa |
| Lumenis Be INC | $281.18 | 2025 | Optilight |
| Shire North American Group INC | $250.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $241.76 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $145.43 | 2023-2024 | Acuvue |
| Harrow Eye, LLC | $130.10 | 2024-2025 | Vevye |
| Allergan, INC. | $123.08 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.01 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $55.85 | 2020 | |
| Dompe US, INC. | $49.72 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $43.33 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $37.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.83 | 2020 | |
| Lkc Technologies, INC. | $23.09 | 2025 | |
| Thea Pharma INC. | $21.67 | 2023 | |
| Abbvie INC. | $21.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Dussan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.